XML 31 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Mortgage Notes, Term Loans, and Secured Revolving Credit Facilities
9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Mortgage Notes, Term Loans, and Secured Revolving Credit Facilities

6. Mortgage Notes, Term Loans, and Secured Revolving Credit Facilities

The following table is a summary of the mortgage notes, term loans, and secured revolving credit facilities secured by the Company’s properties ($ in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Principal Balance Outstanding(3)

 

Indebtedness

 

Weighted

Average

Interest Rate(1)

 

 

Weighted

Average

Maturity Date(2)

 

 

Maximum

Facility Size

 

 

September 30, 2020

 

 

December 31, 2019

 

Fixed rate loans:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fixed rate mortgages

 

3.8%

 

 

7/15/2027

 

 

N/A

 

 

$

12,713,738

 

 

$

12,424,717

 

Mezzanine loan

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

195,878

 

Total fixed rate loans

 

3.8%

 

 

7/15/2027

 

 

 

 

 

 

 

12,713,738

 

 

 

12,620,595

 

Variable rate loans:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Floating rate mortgages

 

L+1.8%

 

 

2/8/2026

 

 

N/A

 

 

 

3,209,340

 

 

 

1,826,435

 

Variable rate term loans

 

L+1.7%

 

 

2/11/2024

 

 

N/A

 

 

 

1,639,495

 

 

 

1,533,561

 

Variable rate secured revolving credit facilities

 

 

 

 

 

 

 

$

2,339,495

 

 

 

 

 

 

1,063,837

 

Variable rate mezzanine loans

 

L+4.3%

 

 

4/9/2025

 

 

N/A

 

 

 

142,200

 

 

 

 

Total variable rate loans

 

L+1.8%

 

 

6/5/2025

 

 

 

 

 

 

 

4,991,035

 

 

 

4,423,833

 

Total loans secured by the Company's properties

 

3.3%

 

 

2/18/2027

 

 

 

 

 

 

 

17,704,773

 

 

 

17,044,428

 

Premium on assumed debt, net

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9,758

 

 

 

10,794

 

Deferred financing costs, net

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(135,499

)

 

 

(125,563

)

Mortgage notes, term loans, and secured revolving credit facilities, net

 

 

 

 

 

 

 

 

 

 

$

17,579,032

 

 

$

16,929,659

 

 

(1)

The term “L” refers to the one-month LIBOR. 

(2)

For loans where the Company, at its sole discretion, has extension options, the maximum maturity date has been assumed.

(3)

The majority of the Company’s mortgages contain yield or spread maintenance provisions.

The following table presents the future principal payments due under the Company’s mortgage notes, term loans, and secured revolving credit facilities as of September 30, 2020 ($ in thousands):

Year

 

Amount

 

2020 (remaining)

 

$

1,790

 

2021

 

 

49,102

 

2022

 

 

553,191

 

2023

 

 

495,174

 

2024

 

 

2,895,943

 

2025

 

 

3,675,311

 

Thereafter

 

 

10,034,262

 

Total

 

$

17,704,773

 

 

 

During the three and nine months ended September 30, 2020, the Company paid off certain of its loans at carrying value in conjunction with the sale of the underlying property or a refinancing. As such, the Company incurred a realized loss on extinguishment of debt of $5.3 million and $6.5 million for the three and nine months ended September 30, 2020, respectively, resulting from the acceleration of related deferred financing costs, prepayment penalties and transactions costs, which are recorded on the Company’s Condensed Consolidated Statements of Operations.

 

The Company is subject to various financial and operational covenants pursuant to certain of the executed mortgage notes, term loans, and secured revolving credit facilities agreements. These covenants require the Company, to maintain certain financial ratios, which may include leverage, debt yield, and debt service coverage, among others. As of September 30, 2020, the Company believes it was in compliance with all of its loan covenants. The Company’s continued compliance with these covenants depends on many factors and could be impacted by current or future economic conditions associated with the COVID-19 pandemic.